Omeros stock skyrockets as narsoplimab improves survival in pivotal TA-TMA trial
Omeros Corporation, a Seattle-based biopharmaceutical company, is making waves after releasing results from its pivotal clinical trial for narsoplimab, a monoclonal antibody designed to treat ... Read More